M Ventures

M Ventures, the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany, was established in 2009. The fund focuses on investments in biotechnology, healthcare, life science tools, electronics, and frontier technologies aimed at sustainability. With a dual focus on strategic and financial returns, M Ventures has a broad investment portfolio that targets transformational ideas and innovative solutions. M Ventures has committed €600 million to support its investments, allowing it to back both early-stage and more advanced companies. The fund has a strong track record with over 115 deals and 86 portfolio startups. Notable investments include companies like Artios Pharma, which focuses on DNA damage response therapies for cancer, and Storm Therapeutics, which specializes in RNA modulation. The venture capital arm takes an active role in its portfolio companies, collaborating closely with entrepreneurs and co-investors to drive innovation and commercial success. M Ventures' strategy includes making early-stage investments and helping companies develop technologies that align with Merck’s long-term R&D goals.